During 2025, the Company reduced its workforce by approximately 27% of full-time employees to align its resources with its ongoing clinical and preclinical programs. There was no expense related to the workforce reduction incurred during the three months ended March 31, 2026 or 2025.

The following table summarizes the accrued liabilities activity recorded in connection with the reduction in workforce for the three months ended March 31, 2026:


(in thousands)	Amount accrued at December 31, 2025		Charges		Amount Paid			Adjustments		Amount accrued at March 31, 2026
Workforce reduction	$	711	$	—	$	(694	)	$	—	$	17